Palatin Technologies, Inc., a specialty biopharmaceutical company, develops targeted receptor-specific therapies for the treatment of various diseases in the United States. The company is headquartered in Cranbury, New Jersey.
| Revenue (TTM) | $12.88M |
| Gross Profit (TTM) | 551,400 |
| EBITDA | $-8.75M |
| Operating Margin | -40.30% |
| Return on Equity | -297.20% |
| Return on Assets | -65.30% |
| Revenue/Share (TTM) | $6.28 |
| Book Value | $5.96 |
| Price-to-Book | 1.85 |
| Price-to-Sales (TTM) | 1.42 |
| EV/Revenue | 0.754 |
| EV/EBITDA | 0.55 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -80.10% |
| Shares Outstanding | $1.78M |
| Float | $1.38M |
| % Insiders | 7.89% |
| % Institutions | 55.58% |
Volatility is currently expanding
PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting the melanocortin receptor system, today announced that its common stock has been approved for listing on the Nasdaq Capital Market and that the Company will transfer its stock exchange listing to Nasdaq from the NYSE American.
Palatin Technologies, Inc. (PTN) Q3 2026 Earnings Call Transcript
